Research Article
Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
Table 5
Univarate analysis of risk factors for overall survival and event free survival in AML.
| | Overall survival | Event free survival | | Median (months) | 95% CI | Log rank | value | Median (months) | 95% CI | Log rank | value |
| | LEF1 low (31) | 16 | 12.5–19.4 | 5.4 | 0.02 | 8 | 5.6–10.3 | 5.5 | 0.019 | | LEF1 high (38) | 20 | 16.9–23.01 | 15 | 11.6–18.3 | | Galectine.3 <5.6 (35) | 21 | 12.9–29.01 | 6.07 | 0.014 | 15 | 6.6–23.3 | 4.7 | 0.02 | | Galectine.3 ≥5.6 (34) | 16 | 12.3–19.6 | 10 | 7.8–12.1 | | Galectine.3 low/LEF1 high (30) | 21 | 13.4–28.5 | 8.2 | 0.04 | 15 | 10.9–19 | 7.7 | 0.052 | | Galectine.3 low/LEF1 low (5) | 18 | 4.9–31.5 | 12 | 4.1–27.3 | | Galectine.3 high/LEF1 high (8) | 20 | 15.9–24.02 | 15 | 4.7–25.2 | | Galectine.3 high/LEF1 low(26) | 13 | 8.2–17.7 | 8 | 5.5–10.4 |
|
|
